Cargando…

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease

BACKGROUND: Corticosteroids, immunomodulators (IM) and tumour necrosis factor antagonists (anti-TNF) are commonly used in the treatment of inflammatory bowel disease (IBD) but they also supress the defence against infectious disease. The aim of this study was to analyse the incidence of infectious e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersson, Per, Karling, Pontus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Academia 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788654/ https://www.ncbi.nlm.nih.gov/pubmed/35140875 http://dx.doi.org/10.48101/ujms.v127.8167

Ejemplares similares

Preclinical Markers in Inflammatory Bowel Disease. A Nested Case–Control Study
por: Lundgren, David, et al.
Publicado: (2021)

Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021)

Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease
por: Ślebioda, Tomasz J., et al.
Publicado: (2014)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Patients developing inflammatory bowel disease have iron deficiency and lower plasma ferritin years before diagnosis: a nested case-control study
por: Widbom, Lovisa, et al.
Publicado: (2020)

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

Matrix Metalloproteinases in Cytotoxic Lymphocytes Impact on Tumour Infiltration and Immunomodulation
por: Edsparr, Karin, et al.
Publicado: (2010)

Patient-reported and doctor-reported symptoms when faecal immunochemical tests are requested in primary care in the diagnosis of colorectal cancer and inflammatory bowel disease: a prospective study
por: Högberg, Cecilia, et al.
Publicado: (2020)

The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic–pituitary–adrenal axis: a retrospective observational study
por: Ibrahim, Aghil, et al.
Publicado: (2017)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Delayed small bowel octreotide response in patients with hereditary transthyretin amyloidosis
por: Jonas, Wixner, et al.
Publicado: (2015)

Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
por: Hong, Seung Wook, et al.
Publicado: (2021)

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
por: Hamdi, Haïfa, et al.
Publicado: (2006)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
por: Wang, Liang-Fang, et al.
Publicado: (2023)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

Irritable bowel syndrome-like symptoms in treated microscopic colitis patients compared with controls: a cross-sectional study
por: Pagoldh, Jenny, et al.
Publicado: (2019)

The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis
por: Yang, Meiqi, et al.
Publicado: (2021)

Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
por: Nyboe Andersen, Nynne, et al.
Publicado: (2015)

Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study
por: Shehab, Mohammad, et al.
Publicado: (2023)

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Holmgren, Johanna, et al.
Publicado: (2022)

A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
por: Mosli, Mahmoud H., et al.
Publicado: (2015)

1728. A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists
por: Harris, Courtney, et al.
Publicado: (2019)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Tumour necrosis factor-dependent inflammatory cartilage destruction
por: Korb, A, et al.
Publicado: (2007)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease
por: Ehrenberg, Rahel, et al.
Publicado: (2020)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
por: Fernández-Villa, Daniel, et al.
Publicado: (2019)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
por: Banse, Christopher, et al.
Publicado: (2013)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Mechanisms of Extracellular Immunomodulation Mediated by Infectious Agents
por: Viejo-Borbolla, Abel, et al.
Publicado: (2017)

Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2020)

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment
por: Marotti, Valentina, et al.
Publicado: (2023)

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
por: Crowe, J. Scott, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0j9c4lm2idc51llssngo7uo8o3